KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Non-Current Deferred Tax Liability (2016 - 2017)

Travere Therapeutics' Non-Current Deferred Tax Liability history spans 5 years, with the latest figure at $16.8 million for Q4 2017.

  • For Q4 2017, Non-Current Deferred Tax Liability rose 161.63% year-over-year to $16.8 million; the TTM value through Dec 2017 reached $16.8 million, up 161.63%, while the annual FY2017 figure was $16.8 million, 161.63% up from the prior year.
  • Non-Current Deferred Tax Liability reached $16.8 million in Q4 2017 per TVTX's latest filing, up from $1.2 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $39.9 million in Q1 2015 to a low of $141000.0 in Q4 2014.
  • Average Non-Current Deferred Tax Liability over 5 years is $11.4 million, with a median of $8.5 million recorded in 2016.
  • Peak YoY movement for Non-Current Deferred Tax Liability: tumbled 94.58% in 2014, then surged 17153.9% in 2015.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $2.6 million in 2013, then crashed by 94.58% to $141000.0 in 2014, then soared by 17153.9% to $24.3 million in 2015, then tumbled by 73.59% to $6.4 million in 2016, then soared by 161.63% to $16.8 million in 2017.
  • Per Business Quant, the three most recent readings for TVTX's Non-Current Deferred Tax Liability are $16.8 million (Q4 2017), $1.2 million (Q2 2017), and $4.4 million (Q1 2017).